Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.
Erin Hattler, Hannah Schluter, Catherine Greene et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on maternal pregnancy complications in 186,598 pregnancies. The study found no significant differences in the odds of gestational diabetes, preterm birth, preeclampsia, or hypertensive disorders. However, sensitivity analysis indicated a potential protective effect against gestational diabetes (OR 0.81, 95% CI, 0.67-0.98).
Key findings
- No significant differences in gestational diabetes (OR 0.99, 95% CI, 0.61-1.61) were observed.
- Preterm birth odds were not significantly affected (OR 1.01, 95% CI, 0.76-1.33).
- Preeclampsia showed no significant association (OR 1.05, 95% CI, 0.60-1.84).
- Sensitivity analysis suggested a potential protective effect against gestational diabetes (OR 0.81, 95% CI, 0.67-0.98).
Why it matters
Understanding the safety profile of GLP-1 RAs during pregnancy is crucial for clinicians managing diabetes in pregnant patients. This study provides evidence that GLP-1 RA exposure does not increase the risk of major maternal complications.
What to keep in mind
The study noted variability in quality and high heterogeneity among included studies due to differences in exposure and outcome definitions.